Genetic causes of Parkinson's disease:: UCHL-1

被引:36
作者
Healy, DG [1 ]
Abou-Sleiman, PM [1 ]
Wood, NW [1 ]
机构
[1] Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England
关键词
Parkinson's disease; ubiquitin proteasome system; alpha synuclein; human;
D O I
10.1007/s00441-004-0917-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ubiquitin proteasome system is an important cellular pathway that ubiquitinates damaged proteins and degrades them via the 26S proteasome. Abnormalities of this pathway can result in molecular protein aggregation and have been associated with Parkinson's disease (PD). UCHL-1, an enzyme central to the system, possesses catalytic hydrolase activity that can hydrolyze peptide-ubiquitin bonds and recycle ubiquitin monomers for re-use in the same process. Recently, UCHL-1 has been shown to possess a second dimerisation-dependent ligase activity and, at least in vitro, this ligase activity promotes alpha synuclein aggregation. UCHL-1 was first implicated in PD by the discovery of an I93M mutation identified in a German sib-pair with probable autosomal dominant PD. Although no further UCHL-1 mutations have been identified, a common non-synonymous S18Y polymorphism has been suggested to reduce disease susceptibility in non-mendelian forms of PD. In vitro functional data support this protective effect, with evidence that S18Y possesses reduced ligase activity compared with wild type UCHL-1. One study has found increased hydrolase activity associated with S18Y, although another study has not. Important issues regarding UCHL-1 and its role in PD remain inconclusive, especially regarding the pathogenicity of the mendelian I93M mutation. This review tries to address some of these uncertainties.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 43 条
  • [1] Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases
    Choi, J
    Levey, AI
    Weintraub, ST
    Rees, HD
    Gearing, M
    Chin, LS
    Li, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) : 13256 - 13264
  • [2] Ciechanover A, 2000, J CELL BIOCHEM, P40
  • [3] Human genome - HapMap launched with pledges of $100 million
    Couzin, J
    [J]. SCIENCE, 2002, 298 (5595) : 941 - 942
  • [4] Parkinson's disease: Mechanisms and models
    Dauer, W
    Przedborski, S
    [J]. NEURON, 2003, 39 (06) : 889 - 909
  • [5] Molecular pathways of neurodegeneration in Parkinson's disease
    Dawson, TM
    Dawson, VL
    [J]. SCIENCE, 2003, 302 (5646) : 819 - 822
  • [6] S18Y polymorphism in the UCH-L1 gene and Parkinson's disease:: Evidence for an age-dependent relationship
    Elbaz, A
    Levecque, C
    Clavel, J
    Vidal, JS
    Richard, F
    Corrèze, JR
    Delemotte, B
    Amouyel, P
    Alpérovitch, A
    Chartier-Harlin, MC
    Tzourio, C
    [J]. MOVEMENT DISORDERS, 2003, 18 (02) : 130 - 137
  • [7] Genome scans and candidate gene approaches in the study of common diseases and variable drug responses
    Goldstein, DB
    Ahmadi, KR
    Weale, ME
    Wood, NW
    [J]. TRENDS IN GENETICS, 2003, 19 (11) : 615 - 622
  • [8] The lle93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease
    Harhangi, BS
    Farrer, MJ
    Lincoln, S
    Bonifati, V
    Meco, G
    De Michele, G
    Brice, A
    Dürr, A
    Martinez, M
    Gasser, T
    Bereznai, B
    Vaughan, JR
    Wood, NW
    Hardy, J
    Oostra, BA
    Breteler, MMB
    [J]. NEUROSCIENCE LETTERS, 1999, 270 (01) : 1 - 4
  • [9] The ubiquitin system
    Hershko, A
    Ciechanover, A
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 : 425 - 479
  • [10] Ubiquitin-dependent protein degradation
    Hochstrasser, M
    [J]. ANNUAL REVIEW OF GENETICS, 1996, 30 : 405 - 439